Immunome (IMNM) Competitors

$20.88 0.00 (0.00%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$20.86 -0.02 (-0.07%)

As of 07:10 AM Eastern

IMNM vs. ABVX, CYTK, PRAX, KRYS, and IBRX

Should you buy Immunome stock or one of its competitors? MarketBeat compares Immunome with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunome include Abivax (ABVX), Cytokinetics (CYTK), Praxis Precision Medicines (PRAX), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Immunome compare to Abivax?

Immunome (NASDAQ:IMNM) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Immunome has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market. Comparatively, Abivax has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Immunome currently has a consensus price target of $32.82, suggesting a potential upside of 57.18%. Abivax has a consensus price target of $137.15, suggesting a potential upside of 19.75%. Given Immunome's higher probable upside, equities research analysts plainly believe Immunome is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Immunome's return on equity of -51.15% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Abivax	N/A	-146.43%	-88.69%

44.6% of Immunome shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immunome has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	340.73	-$212.39M	-$2.38	N/A
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A

In the previous week, Immunome had 18 more articles in the media than Abivax. MarketBeat recorded 23 mentions for Immunome and 5 mentions for Abivax. Immunome's average media sentiment score of 0.88 beat Abivax's score of 0.84 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunome beats Abivax on 11 of the 14 factors compared between the two stocks.

How does Immunome compare to Cytokinetics?

Immunome (NASDAQ:IMNM) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Immunome has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Immunome has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Cytokinetics	-784.02%	N/A	-52.86%

Immunome currently has a consensus price target of $32.82, suggesting a potential upside of 57.18%. Cytokinetics has a consensus price target of $98.55, suggesting a potential upside of 29.93%. Given Immunome's stronger consensus rating and higher probable upside, equities research analysts plainly believe Immunome is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82

Immunome has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	340.73	-$212.39M	-$2.38	N/A
Cytokinetics	$88.04M	107.20	-$784.96M	-$6.84	N/A

44.6% of Immunome shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Immunome had 2 more articles in the media than Cytokinetics. MarketBeat recorded 23 mentions for Immunome and 21 mentions for Cytokinetics. Immunome's average media sentiment score of 0.88 beat Cytokinetics' score of 0.46 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immunome beats Cytokinetics on 13 of the 16 factors compared between the two stocks.

How does Immunome compare to Praxis Precision Medicines?

Immunome (NASDAQ:IMNM) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Immunome has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market.

In the previous week, Immunome had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 23 mentions for Immunome and 19 mentions for Praxis Precision Medicines. Immunome's average media sentiment score of 0.88 beat Praxis Precision Medicines' score of 0.21 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

44.6% of Immunome shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Praxis Precision Medicines' return on equity of -43.02% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Immunome presently has a consensus price target of $32.82, suggesting a potential upside of 57.18%. Praxis Precision Medicines has a consensus price target of $592.67, suggesting a potential upside of 73.00%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

Immunome has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	340.73	-$212.39M	-$2.38	N/A
Praxis Precision Medicines	$8.55M	1,117.09	-$303.27M	-$13.37	N/A

Summary

Praxis Precision Medicines beats Immunome on 10 of the 16 factors compared between the two stocks.

How does Immunome compare to Krystal Biotech?

Immunome (NASDAQ:IMNM) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Immunome has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

In the previous week, Immunome had 15 more articles in the media than Krystal Biotech. MarketBeat recorded 23 mentions for Immunome and 8 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.04 beat Immunome's score of 0.88 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

44.6% of Immunome shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to Immunome's net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Krystal Biotech	53.92%	19.25%	17.62%

Immunome presently has a consensus price target of $32.82, suggesting a potential upside of 57.18%. Krystal Biotech has a consensus price target of $324.11, suggesting a potential upside of 5.82%. Given Immunome's stronger consensus rating and higher possible upside, equities analysts clearly believe Immunome is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	340.73	-$212.39M	-$2.38	N/A
Krystal Biotech	$389.13M	23.20	$204.83M	$7.48	40.95

Summary

Krystal Biotech beats Immunome on 10 of the 16 factors compared between the two stocks.

How does Immunome compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Immunome has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$140.98M	59.21	-$351.40M	-$0.85	N/A
Immunome	$6.94M	340.73	-$212.39M	-$2.38	N/A

ImmunityBio has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, Immunome has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market.

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 78.17%. Immunome has a consensus price target of $32.82, suggesting a potential upside of 57.18%. Given ImmunityBio's higher probable upside, research analysts clearly believe ImmunityBio is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Immunome	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, ImmunityBio had 21 more articles in the media than Immunome. MarketBeat recorded 44 mentions for ImmunityBio and 23 mentions for Immunome. Immunome's average media sentiment score of 0.88 beat ImmunityBio's score of 0.21 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	5 Very Positive mention(s)	1 Positive mention(s)	30 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Immunome	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 69.5% of ImmunityBio shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Immunome has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Immunome	N/A	-51.15%	-47.32%

Summary

Immunome beats ImmunityBio on 10 of the 16 factors compared between the two stocks.

Get Immunome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNM vs. The Competition

Export

Metric	Immunome	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.36B	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.81%	5.30%
P/E Ratio	-8.77	18.50	20.40	25.26
Price / Sales	340.73	287.14	549.89	73.54
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	3.63	6.76	9.75	6.71
Net Income	-$212.39M	$24.40M	$3.57B	$336.00M
7 Day Performance	-9.22%	-1.08%	-1.01%	-0.72%
1 Month Performance	-15.23%	-4.84%	-2.59%	-0.09%
1 Year Performance	159.06%	62.87%	33.53%	30.62%

Immunome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNM Immunome	3.2822 of 5 stars	$20.88 flat	$32.82 +57.2%	+159.1%	$2.36B	$6.94M	N/A	40	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up
ABVX Abivax	3.6031 of 5 stars	$122.13 -0.5%	$137.15 +12.3%	+1,805.7%	$9.73B	N/A	N/A	61	Upcoming Earnings Gap Up
CYTK Cytokinetics	2.6163 of 5 stars	$74.56 -3.1%	$97.45 +30.7%	+144.7%	$9.57B	$88.04M	N/A	250	Gap Up
PRAX Praxis Precision Medicines	3.3474 of 5 stars	$331.81 +0.5%	$591.83 +78.4%	+825.4%	$9.20B	$8.55M	N/A	110
KRYS Krystal Biotech	3.1206 of 5 stars	$312.88 +2.3%	$324.11 +3.6%	+134.5%	$9.01B	$389.13M	41.83	210	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNM) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Competitors

IMNM vs. ABVX, CYTK, PRAX, KRYS, and IBRX

How does Immunome compare to Abivax?

Summary

How does Immunome compare to Cytokinetics?

Summary

How does Immunome compare to Praxis Precision Medicines?

Summary

How does Immunome compare to Krystal Biotech?

Summary

How does Immunome compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Competitors

IMNM vs. ABVX, CYTK, PRAX, KRYS, and IBRX

How does Immunome compare to Abivax?

Which has more volatility & risk, IMNM or ABVX?

Do analysts rate IMNM or ABVX?

Is IMNM or ABVX more profitable?

Do insiders & institutionals have more ownership in IMNM or ABVX?

Which has better earnings & valuation, IMNM or ABVX?

Does the media prefer IMNM or ABVX?

Summary

How does Immunome compare to Cytokinetics?

Which has more volatility & risk, IMNM or CYTK?

Is IMNM or CYTK more profitable?

Do analysts rate IMNM or CYTK?

Which has better earnings & valuation, IMNM or CYTK?

Do insiders & institutionals have more ownership in IMNM or CYTK?

Does the media prefer IMNM or CYTK?

Summary

How does Immunome compare to Praxis Precision Medicines?

Which has more volatility and risk, IMNM or PRAX?

Does the media favor IMNM or PRAX?

Do insiders and institutionals have more ownership in IMNM or PRAX?

Is IMNM or PRAX more profitable?

Do analysts recommend IMNM or PRAX?

Which has better valuation & earnings, IMNM or PRAX?

Summary

How does Immunome compare to Krystal Biotech?

Which has more volatility and risk, IMNM or KRYS?

Does the media favor IMNM or KRYS?

Do insiders and institutionals have more ownership in IMNM or KRYS?

Is IMNM or KRYS more profitable?

Do analysts recommend IMNM or KRYS?

Which has better valuation & earnings, IMNM or KRYS?

Summary

How does Immunome compare to ImmunityBio?

Which has stronger valuation and earnings, IBRX or IMNM?

Which has more risk and volatility, IBRX or IMNM?

Do analysts recommend IBRX or IMNM?

Does the media refer more to IBRX or IMNM?

Do institutionals and insiders have more ownership in IBRX or IMNM?

Is IBRX or IMNM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools